Defender Pharmaceuticals Announces Collaboration with NASA on Two Phase 2 Clinical Trials Investigating DPI-386’s Ability to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
First study evaluates DPI-386 alone and in combination with sensory augmentation to effectively mitigate motion sickness and improve task performance, in comparison to placebo.
- First study evaluates DPI-386 alone and in combination with sensory augmentation to effectively mitigate motion sickness and improve task performance, in comparison to placebo.
- Second study evaluates the feasibility and efficacy of administering DPI-386 in operational field settings, with both astronaut and ground-control subjects, when exposed to provocative motion.
- Both trials are being led by primary investigator Scott J Wood, PhD of NASA, and Neuroscience Laboratory Principal Investigator.
- As the only clinical pharmacologist at NASA, Dr. Putcha was responsible for directing and conducting the research and development program for optimizing pharmacotherapeutics in space.